OA1-1 Unanticipated participant benefits in HIV cure clinical research: a qualitative analysis
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Background {#jve1_1-1-sec-0001}
==========

Early-phase HIV cure research involves substantial and often unknown risks, with no direct participant health benefits. During informed consent and subsequent study visits, researchers emphasize this lack of benefit with the intent of minimizing misconceptions that undermine genuine consent. We explored what, if any, social, psychological, and/or emotional benefits exist for HIV cure study participants. Accordingly, we considered the significance of these often unrecognized benefits and how they may impact responsible conduct of research.

Methods {#jve1_1-1-sec-0002}
=======

We conducted in-depth, semi-structured interviews with 33 adults, including 15 HIV cure research participants, ten research staff (e.g. participant screeners, research coordinators), and eight bench scientists or physician-researchers in Chapel Hill and Durham, North Carolina, USA. Interviews were audio-recorded, transcribed, and then coded and analysed using MAXQDA® to identify themes related to participants' experiences and perceptions of research benefits.

Results {#jve1_1-1-sec-0003}
=======

The 15 HIV cure participant-interviewees were all men with a median age of 48 (range: 28--62 years). Most were white (13/15); one was Black, and one Latino. Ten of 15 participants self-identified as gay. All 15 participant-interviewees reported benefits related to cure research, including improved HIV knowledge/awareness (14/15); improved healthcare (12/15); improved personal relationships (8/15); and positive behavioural changes (6/15). Fourteen participant-interviewees described psychological/emotional benefits, including a sense of helping others. Other benefits included: sense of purpose, increased self-worth, and emotional support through interactions with research team members. Five participant-interviewees expressed intent to continue in cure research for as long as possible; two indicated that only death would stop them from participating in cure research. Among researchers and staff, social, psychological, and/or emotional participant benefits were only mentioned in roughly half of the interviews -- suggesting less emphasis on these benefits.

Conclusions {#jve1_1-1-sec-0004}
===========

We observed substantial unanticipated social, psychological, and emotional benefits associated with HIV cure research. These are important and are often the primary reasons participants continue to take part in studies. Participants felt they were taking part in something important and larger than themselves. These benefits, while subjective and contingent, should be considered when recruiting participants and are important for informed consent processes.

OA1-2 Ethical and social implications of proposed HIV cure research: stakeholder perspectives from South Africa
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Background {#jve1_1-2-sec-0001}
==========

The ethical concerns associated with HIV prevention and treatment research have been widely explored in South Africa. However, HIV cure research is relatively new to the region and significant ethical and social challenges are anticipated as various scientific strategies including early treatment of acute infection, neutralizing antibodies, gene therapy and therapeutic vaccines are explored. Consequently, early stakeholder engagement is critical. While two studies in China and Australia have researched stakeholder perspectives, there has been no similar published empirical enquiry in Africa regarding HIV cure research. This study was conducted to gain preliminary data from South African HIV clinicians, patients, caregivers, medical students, researchers and activists.

Methods {#jve1_1-2-sec-0002}
=======

In-depth interviews were conducted on a purposive sample of thirty-five stakeholders in South Africa from October 2015 to February 2016. In addition five focus group discussions (FGDs) were conducted with adolescent patients, caregivers, adult patients, Community Advisory Board members and medical students. Audiotaped interviews and FGDs were transcribed verbatim with concurrent thematic analysis. Analyst triangulation occurred as the data were analysed by three researchers independently and then integrated via discussion.

Results {#jve1_1-2-sec-0003}
=======

Common themes emerged from the interviews. The rapid evolution of HIV cure research agendas was prominent with participants expressing some concern that the global North was driving the cure agenda. Assessing and managing knowledge and expectations around HIV cure research emerged as a central theme related to challenges to constructing 'cure'. Distinguishing between biomedical and emotional cure, remission and healing was highlighted as important. Avoiding curative misconception would be critical. Treatment interruption was regarded as a major risk if "cure" failed.

Conclusions {#jve1_1-2-sec-0004}
===========

A holistic approach integrating biomedical treatment, prevention and cure research is critical to achieve HIV eradication. The synergistic effect of such scientific research will be enhanced if the social and ethical dimensions of cure are taken into account. The findings of this study have important implications for community engagement, consent processes and possibly compensation for failed interventions in future cure trials. Undoubtedly, knowledge and resource sharing in the context of collaboration between research scientists working in cure and those working in treatment and prevention will accelerate progress towards cure.

OA1-3 Factors affecting participation in HIV cure-related research in the United States: implications for effective and ethical implementation
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Background {#jve1_1-3-sec-0001}
==========

We investigated willingness to participate in HIV cure-related research among potential volunteers in the United States, focusing on perceived personal and societal risks and benefits of participation.

Methods {#jve1_1-3-sec-0002}
=======

We conducted an online cross-sectional survey among 400 U.S. adults living with HIV (22% female, 77% male, \<1% transgender) in September -- October 2015, with an ethnically diverse sample (65% Caucasian, 17% African-American, 12% Hispanic, 4% mixed and 2% Asian) from 38 U.S. states. We also conducted extensive key informant interviews with 36 people living with HIV, as well as researchers, bioethicists, members of IRBs and regulatory agencies to assess perceptions of risks and benefits.

Results {#jve1_1-3-sec-0003}
=======

Increased cancer risk (49% \[95% CI: 42, 52%\]; n=358), developing resistance to ARVs (37% \[32, 42%\]; n=358), toxicities (30% \[25, 35%\]; n=358) and risks of stopping HIV medications (30% \[25, 35%\]; n=358) were the potential clinical risks most likely to discourage participation among people living with HIV. Perceptions of "too much risk" ranged from first-in-human studies without underlying proof of concept, painful procedures, significant increases in viral load and decreases in CD4, interventions causing viral rebound, irreversible long-term side effects, damages to vital organs, immune system shut down, anything that would cause HIV to become unmanageable, progression to AIDS, hospitalization, debilitation or risk of death. The psychological benefit of feeling good about contributing to HIV cure research (80%, 95% CI: \[75--85%\]; n=396) and gaining knowledge about one\'s health (78% \[73--83%\]; n=385) were the potential personal benefits most likely to motivate participation. After controlling for socio-demographic variables, perceptions of 5 potential benefits and 19 risks were statistically significant motivating and demotivating factors correlated with willingness to participate. Key informants discussed requirements of research ethics, study design issues and logistical factors affecting participation in and implementation of HIV cure studies.

Conclusions {#jve1_1-3-sec-0004}
===========

Understanding perceptions of risks and benefits is important to inform study design, informed consent, and recruitment and retention strategies for HIV cure-related research. The discourse around the effective and ethical implementation of HIV cure research will require further input from a variety of sources.

OA2-1 Frequent and 'burst-like' reactivation from latency in SIVmac239M infected macaques
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Background {#jve1_2-1-sec-0001}
==========

Anti-retroviral treatment interruption is usually followed by the recrudescence of infection within a few weeks. This is thought to arise from the reactivation and viral production of a number of latently infected cells. However, very little is known about the basic dynamics of reactivation from latency, such as the frequency of latent cell reactivation, whether reactivated cells live for a prolonged period, how much virus they produce, and whether they die following reactivation. We have developed a novel system of 'tagged' viruses to study the reactivation of individual latent cell 'reactivation founders' and combine this with viral dynamics modeling to better understand HIV reactivation.

Methods {#jve1_2-1-sec-0002}
=======

Rhesus macaques were infected with 2.2×10∧5 IU of a modified SIVmac239 containing an SIV population with ≈10,000 different clonotypes differing only at a 34 bp 'tag' inserted between the Vpx and Vpr genes (SIVmac239M). Animals were treated with TFV/FTC/RAL at day 6 for 82 days (n=3, group 1), or with TFV/FTC/IND/RTV on day 4 for \>300 days (n=2, group 2) prior to treatment interruption. Illumina sequencing was used to identify the frequency of individual clonotypes following treatment interruption.

Results {#jve1_2-1-sec-0003}
=======

All animals showed a diversity of SIVmac239M clonotypes in serum prior to treatment, and rapid recrudescence of infection after treatment interruption. Analysis of the number and relative size of individual reactivation founder clonotypes revealed that between 3 and 63 unique clonotypes were detectable in different animals. Modeling of the ratios of the clonotypes in different animals showed that the frequency of reactivation from latency ranged from 27.3 reactivations per day to 0.46 per day. Moreover, the ratio of clonotypes also showed that the duration of viral production from individual latent after reactivation must be "burst-like" in order to produce the observed frequencies.

Conclusions {#jve1_2-1-sec-0004}
===========

The use of 'tagged' SIVmac239M is an extremely powerful tool for analyzing the dynamics of HIV reactivation from latency. Analysis of the reactivating clonotypes shows that the frequency of reactivation is higher in animals treated for shorter periods of time. The rapid 'burst-like' production of virus from reactivated cells suggests that these cells may be short lived following reactivation.

OA2-2 Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART
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Background {#jve1_2-2-sec-0001}
==========

For the improved design of strategies towards HIV-1 functional cure, it is important to identify biomarkers that could predict the duration of post-treatment virological control.

Methods {#jve1_2-2-sec-0002}
=======

We studied 46 patients that received 24 or 60 weeks of temporary ART initiated at primary HIV infection (PHI). Patients were treated with a quadruple triple-class ART regimen. Cell-associated HIV-1 nucleic acids were quantified by seminested real-time PCR.

Results {#jve1_2-2-sec-0003}
=======

All patients achieved virological suppression (VS) (plasma HIV-1 viremia \<50 copies/ml) with a median of 21 weeks. We first assessed the predictive power of plasma viremia, total HIV-1 DNA, unspliced (US) cell-associated HIV-1 RNA, CD4^+^ T-cell count, and CD4:CD8 ratio, measured at PHI, for the time to VS. In the univariate analysis, both plasma viremia and US RNA were predictive for time to VS (p=0.016 and p=0.0033, respectively, log-rank test). In the multivariate Cox regression, US RNA at PHI was the only significant predictor of the time to VS (HR=0.65 per 1 log~10~increase in US RNA, 95% CI, 0.48--0.87, p=0.0043). Subsequently, the same biomarkers were longitudinally quantified every 12 weeks during ART. All 45 patients who discontinued ART experienced virological rebound (VR) (plasma viremia \>50 copies/ml) within 9 months after therapy interruption. We assessed the predictive power of the last measurements of the biomarkers on ART before the therapy interruption, as well as of the duration of temporary ART, for the time to VR (the duration of post-treatment virological control). Again, US RNA was the only significant predictor of the time to VR (HR=0.29 for patients with US RNA levels below vs. above the median, 95% CI, 0.10--0.83, p=0.021, log-rank test).

Conclusions {#jve1_2-2-sec-0004}
===========

In summary, in this cohort of patients treated at PHI, cell-associated HIV-1 US RNA level was the sole independent predictor of both virological suppression on ART and post-treatment virological control after ART discontinuation. Further exploration of the potential of this biomarker as a predictor of post-treatment control in large-scale clinical trials aimed at HIV functional cure is warranted.

OA2-3 BCL-2 antagonism decreases HIV replication and infected cell survival in acute

in vitro
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Background {#jve1_2-3-sec-0001}
==========

Following HIV integration and establishment of latency, integrated provirus may remain latent for years, or may be reactivated and replicate progeny virions. Replication of HIV activates HIV protease, which generates an HIV-specific cleavage product of Caspase 8 called Casp8p41. Under normal circumstances Casp8p41 translocates to mitochondria, where it activates Bak oligomerization and initiates apoptosis. Recently we demonstrated that in central memory CD4 T cells, BCL-2 expression is increased, and that Casp8p41 binds instead to BCL-2, thereby preventing the death of central memory CD4 T cells which reactivate HIV. Importantly however treating cells with the BCL-2 specific inhibitor venetoclax causes latently infected CD4 T cells from HIV infected patients to die following HIV reactivation. In the current study we evaluated the effects of venetoclax in acute HIV infection of CD4 T cells, by analyzing viral replication, cell viability and proportion of cells containing cell associated HIV DNA.

Methods {#jve1_2-3-sec-0002}
=======

Activated primary CD4 T cells were infected with HIV IIIb in the presence or absence of venetoclax or diluent control. The following were analyzed over time: cell death by flow cytometry; HIV replication by supernatant p24 levels; cell associated HIV DNA by qPCR.

Results {#jve1_2-3-sec-0003}
=======

Venetoclax did not significantly reduce survival of mock-infected, activated primary CD4 T cells at a dose consistent with achievable plasma concentrations in vivo (1 μM), consistent with the favorable safety profile of venetoclax in clinical trials. In contrast, when primary activated CD4 T cells from 7 donors were infected with HIV and analyzed for survival over 9 days, venetoclax reduced survival of the infected cells compared to vehicle control (P=0.039). These results suggest that HIV infected cells might be dying preferentially in response to venetoclax. Consistent with this possibility, HIV infected cultures treated with venetoclax had decreased cell associated HIV-1 DNA compared to vehicle control treated cells (mean difference −35%, P=0.021), and reduced p24 production in cultures treated with venetoclax compared to vehicle control (mean difference −24.4%, P=0.032). Similar results were seen with navitoclax, an inhibitor of BCL-2, BCL-X~L~, and BCL-W, although there was increased non specific toxicity.

Conclusions {#jve1_2-3-sec-0004}
===========

The latent reservoir for HIV represents the main barrier for HIV cure, as it is unaffected by current ART, and is not reduced following HIV reactivation from latency. Clinically available BCL-2 inhibitors result in reduced HIV DNA levels following acute HIV infection *in vitro*, and reduce cell associated HIV DNA levels following reactivation of primary CD4 T cells from latency when studied *ex vivo*, and therefore warrant further study.

OA2-4 Enhancing HIV-1 virion tethering by BST2/tetherin sensitizes productively and latently infected T cells to ADCC mediated by broadly neutralizing anti-HIV antibodies
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Background {#jve1_2-4-sec-0001}
==========

Increasing evidence supports a role of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) in controlling HIV transmission and disease progression. HIV has evolved several mechanisms to limit the recognition of ADCC-preferred Env epitopes on infected cells. We previously reported that HIV-1 uses Nef- and Vpu-mediated CD4 downregulation to efficiently reduce exposure of Env epitopes recognized by A32, a non-neutralizing, CD4-induced ADCC-competent antibody. Moreover, BST2 antagonism by Vpu limits A32 binding to gp120 on infected cells. BST2 is a type I interferon (IFN)-upregulated restriction factor that inhibits HIV-1 release by tethering nascent virions at the surface of infected cells. In this study, we hypothesized that broadly neutralizing anti-HIV antibodies (bNAbs) can also mount ADCC response and that in this context, physical tethering of virions by BST2 will promote ADCC.

Methods {#jve1_2-4-sec-0002}
=======

Primary CD4+ T cells or T cells expressing only CD4, BST2, or both were infected with wild-type (WT) HIV or viruses deficient for Nef, Vpu or both proteins. Infected T cells were examined by flow cytometry for Env recognition by anti-HIV Env antibodies and susceptibility to ADCC.

Results {#jve1_2-4-sec-0003}
=======

Using CD4+ T cells infected with CCR5-tropic laboratory-adapted or transmitted-founder HIV strains, we show that bNAbs efficiently induce ADCC, with those targeting the N332 glycan-V3 loop (*e.g*., PGT121 or PGT126) or CD4-binding site (*e.g*., 3BNC117) being most potent. For most bNAbs, BST2 counteraction effectively attenuates Env recognition and ADCC activity. Conversely, IFNα treatment enhances antibody binding to Env and potentiates ADCC in a BST2-dependent manner. Importantly, upon reactivation with HDAC inhibitors, latently infected T cells become potent targets of ADCC, with exogenous IFNα promoting further their elimination by bNAbs such as PGT121. Lastly, we find that modulating the levels of surface gp120 in a CD4-bound conformation, via Vpu and Nef, affects ADCC activity of only 17b, which binds the co-receptor binding site.

Conclusions {#jve1_2-4-sec-0004}
===========

Overall, our study indicates that physical retention of HIV virions by BST2 at the cell surface sensitizes infected cells to ADCC by most classes of bNAbs. Strategies aimed at restoring the BST2 restriction represent a promising avenue to enhance clearance of latent viral reservoirs by ADCC in ʺShock and Killʺ cure approaches.

OA2-5 LB No evidence of ongoing replication in tissue compartments during combination antiretroviral therapy
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Background {#jve1_2-5-sec-0001}
==========

Sources of HIV persistence during combination antiretroviral therapy (cART) remains uncertain, and the contribution of active cycles of HIV replication in tissue compartments is unknown. Genetic analyses are sensitive measures to detect ongoing cycles of virus replication, particularly in individuals who undergo cART early after infection, when HIV populations are relatively monomorphic and increases in genetic diversity are easily detectable. To investigate whether ongoing replication occurs in tissues, we studied HIV populations in blood and anatomic compartments from 3 individuals who initiated antiretroviral therapy shortly after HIV infection and maintained viral suppression for \>8 y.

Methods {#jve1_2-5-sec-0002}
=======

Samples from three individuals in IRB-approved studies were studied. Individuals started cART soon after infection, maintained HIV RNA\<50 c/ml for 8--16 y, and underwent autopsy for primary effusion lymphoma (N=1), or colonoscopy (N=2). HIV from autopsy was quantified (RT-PCR), and HIV sequences (*pro-pol*, 1200 nt) were obtained from tissues and peripheral blood lymphocytes (PBL) using single genome sequencing (SGS). Sequences were aligned, subjected to phylogenetic (MEGA), and compartmentalization (Slatkin-Maddison, FST, geographic subdivision) analyses; 263 sequences from autopsy and 293 from individuals undergoing colonoscopy were analyzed.

Results {#jve1_2-5-sec-0003}
=======

HIV DNA was detected in most tissues at autopsy (median 1.8 copies/1e6 cells, range 1--75/1e6 cells). HIV had limited genetic diversity in tissues and PBL (average pairwise difference, APD 0.3--0.6%). From the autopsy, PBL (N=124), spleen (38), lymph node (30), ileum (30), jejunum (12), colon (5), effusion cells (10), kidney (5), lung (3), testes (1) were obtained; no HIV was recovered from frontal lobe, spinal cord, or the cell-free effusion fluid. HIV populations were well-mixed in tissues and non-divergent from PBL-derived HIV, with no evidence of compartmentalization in any tissue. Identical hypermutated sequences in PBL and several tissues demonstrated distribution of clonally expanded cells had occurred. In 2 individuals undergoing colonoscopy, analysis of HIV from ileum, colon, and PBL revealed no evidence of ongoing replication and no divergence from pretherapy plasma RNA obtained 12--16 years prior to colonoscopy.

Conclusions {#jve1_2-5-sec-0004}
===========

No evidence of ongoing replication was detected in tissues compared to peripheral blood in individuals undergoing cART, suggesting combination antiretroviral therapy blocks active HIV replication, including in tissues.

OA3-1 Allogeneic stem cell transplantation in HIV-1-infected individuals; the EPISTEM consortium
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Background {#jve1_3-1-sec-0001}
==========

To date, the only and most compiling evidence of a medical intervention that has been able to cure HIV-1 infection (the "Berlin patient"), involved an allogeneic stem cell transplant (SCT) from a donor who was homozygous for CCR5Δ32. Although this high-risk procedure is only indicated for certain hematological malignancies, the strategy raised tremendous scientific potential to gain insight in the mechanisms of HIV eradication.

Methods {#jve1_3-1-sec-0002}
=======

The EpiStem consortium aims to guide clinicians of HIV infected patients who require an SCT in donor search and CCR5 screening, ethical regulations, the SCT procedure, sampling procedures and in depth investigations to study HIV persistence. The patients are included in the EPISTEM observational cohort. Detailed analysis of the cohort should provide insight as to whether additional factors such as conditioning regimen, total body irradiation and graft versus host disease may contribute to the eradication of the potentially infectious viral reservoir in addition to the lack of a functional CCR5 receptor.

Results {#jve1_3-1-sec-0003}
=======

Nearly 30,000 cord blood units in multiple European blood banks and more than 1.000.000 adult donors have been genotyped for CCR5 to generate a registry of CCR5Δ32 available donors. Twenty HIV positive patients with diverse hematological malignancies have been registered to the EPISTEM cohort. Since 2012, 13 patients have been transplanted; 4 with a CCR5Δ32, 1 with a heterozygous, and 8 with a CCR5 WT donor. In 3 cases the donor cells came from cord blood and in 10 cases from an adult donor. So far, 5 patients have successfully passed the 12 months follow-up after transplantation, and 8 patients have died after transplantation, despite achieving full donor chimerism in most cases. Preliminary analysis of virological and immunological data from blood and tissue samples shows a systematic reduction of HIV-1 reservoirs to very low levels.

Conclusions {#jve1_3-1-sec-0004}
===========

EPISTEM is actively recruiting new cases and continues to systematically investigate HIV persistence over time to gain insight in potential HIV-1 eradication.

OA3-2 CCR5 gene edited cells traffic to viral reservoir tissues and undergo SHIV-dependent positive selection in nonhuman primates
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Background {#jve1_3-2-sec-0001}
==========

Gene editing of the CCR5 coreceptor locus in hematopoietic stem/progenitor cells (HSPCs) is a promising therapy for HIV infection. We have previously demonstrated the feasibility of this approach in nonhuman primates. Here, we leverage our expertise with gene editing in the pigtailed macaque, *M. nemestrina* to interrogate the clonal persistence, trafficking, and antiviral efficacy of CCR5-edited cells. Our objectives were to understand how individual gene-edited HSPCs persist following autologous transplantation and virus infection, determine whether HSPC-derived, gene-edited progeny traffic to viral reservoir tissues, and develop strategies to increase the number of these cells *in vivo.*

Methods {#jve1_3-2-sec-0002}
=======

Zinc Finger Nucleases (ZFNs) are used to target the CCR5 locus in macaque HSPCs. Gene edited HSPCs are transplanted into animals either prior to infection with simian/human immunodeficiency virus (SHIV), or in SHIV-infected animals that are treated with a combination antiretroviral therapy (cART) regimen designed to approximate a well-suppressed HIV^+^ patient. Edited cells are measured in peripheral blood, bone marrow, gastrointestinal (GI) tract, lymph nodes, and at necropsy in a panel of 25 tissues, using methods including deep sequencing.

Results {#jve1_3-2-sec-0003}
=======

We observe up to 14-fold enrichment of CCR5-gene edited memory CD4^+^ T-cells in SHIV-infected animals, consistent with virus-dependent selection against CCR5 wt memory CD4^+^ T-cells. Gene edited cells are found in a broad array of anatomical sites. These include tissues that we have identified as viral reservoirs in our model, namely GI tract and lymph nodes. Spatial and temporal tracking of CCR5 mutations suggests that gene edited cells persist long-term, and are polyclonal. Homology directed repair (HDR) pathways can be exploited in macaque CD34^+^ HSPCs, facilitating knock-in of selectable markers at the disrupted CCR5 locus.

Conclusions {#jve1_3-2-sec-0004}
===========

Our gene editing strategy results in stable engraftment of CCR5-mutated and SHIV-resistant HSPCs and their progeny in blood, and in tissues known to serve as viral reservoirs. Importantly, gene-edited CD4^+^ T-cells undergo positive selection during active infection, further supporting the validity of this approach in the clinic. Our preliminary *ex vivo* HDR data suggest that these gene-edited cells could be engineered to undergo positive selection without the need for ongoing viral replication.

OA3-3 Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle can prevent the selection of resistance
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Background {#jve1_3-3-sec-0001}
==========

HIV presents one of the highest mutation rates, which in combination with a fast replication rate and a large population size accelerates viral evolution. Combination antiretroviral therapy can overcome the plasticity of the virus population and profoundly control viral replication. However, conventional treatment lacks the ability to stop viral production and clear the latent reservoir, which remains the major obstacle towards cure. Novel strategies, such as CRISPR/Cas9 genome editing, are required to permanently disrupt the HIV genome in the latently infected cells. In this study we investigated the ability of HIV to escape the CRISPR/Cas9 endonucleases targeting different steps in the viral life cycle.

Methods {#jve1_3-3-sec-0002}
=======

The CRISPR/Cas9 system is comprised of a Cas9 protein, which in combination with a guideRNA (gRNA), is able to cleave a complementary dsDNA sequence. gRNAs were designed to target HIV-LTR, protease, reverse transcriptase, integrase and matrix. The CRISPR/Cas9 system was cloned in a lentivirus vector and transduced in SupT1 cells and the J.Lat Full-Length Clone 15-4. In the latter cells, impact of CRISPR/Cas9 on HIV reactivation was investigated. Transduced SupT1 cells were infected with HIV and viral replication and escape was monitored. On- and off-targeting efficiency (three genes per gRNA) and viral escape was assessed by deep sequencing.

Results {#jve1_3-3-sec-0003}
=======

The CRISPR/Cas9 endonuclease induced efficient HIV genome editing (75%-99%), while off-target efficiency was \<0.9%. Subsequent TNFα-induced HIV reactivation was significantly reduced (single gRNA (40%-95%); two gRNAs (\>98%)). We also demonstrated a significant reduction of HIV replication after six days of culture in SupT1 cells (single gRNA (82%-97%); two gRNAs (93%-99%)). Reduction in viral replication could be directly correlated to the number of CRISPR/Cas9 induced changes in the target sites (mostly indels). Independent of the potency of the gRNAs, selection of resistance was observed for all single gRNAs. However, all combinations of two potent gRNAs resulted in the generation of such a large number of CRISPR/Cas9 induced mutations (mostly indels) that viral replication could not be rescued after months of in vitro selection.

Conclusions {#jve1_3-3-sec-0004}
===========

This is the first study to demonstrate that combining potent gRNAs targeting different steps in the viral lifecycle can prevent the selection of viral resistance.

OA3-4 LB Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor
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Background {#jve1_3-4-sec-0001}
==========

Several classes of HIV-1 latency reversing agents (LRAs) including PKC agonists and HDACis have been investigated for their effects against latent HIV-1 infection. Although many LRAs were capable of reactivating latent HIV-1, it is less certain if they can actually reduce the latent viral reservoirs. To identify potent LRAs that can effectively eliminate/reduce latent HIV-1 reservoirs, we investigated the PKC agonist gnidimacrin (GM) alone and in combination with a selective HDAC inhibitor thiophenyl benzamide (TPB) for their effectiveness on elimination of HIV-1 latently infected cells.

Methods {#jve1_3-4-sec-0002}
=======

1\) cell line model: U1 cells were treated with various concentrations of GM with/without the presence of TPB. The culture supernatant was then collected for P24 ELISA to quantify latent HIV-1 activation; 2) *ex vivo* model: PBMCs from HIV+ patients (with \>5 years of ART and undetectable viral load) were treated with GM, GM+TPB, or vorinostat in the presence of anti-retroviral agents. The viral DNA in the lately infected cells were quantified with RT-PCR and the frequency of latently infected cells was determined by using a limiting dilution viral outgrowth assay.

Results {#jve1_3-4-sec-0003}
=======

In U1 model, the EC~50~of GM was 18 pM for latent viral activation and its potency was enhanced about three-fold in the presence of TPB. In *ex vivo* model, GM alone (20 pM) was able to reduce pro-viral DNA and the frequency of latently infected cells by 5--10 folds. Addition of TPB further increased the effect of GM by over three-fold.

Conclusions {#jve1_3-4-sec-0004}
===========

The results of this study demonstrate that GM is an extremely potent LRA that can effectively reduce HIV-1 latently infected cells *ex vivo* at pM concentrations. In the presence of TPB, the effect of GM was further enhanced. TPB exhibited good selectivity with no overlapping cytotoxic and effective doses in contrast to other tested HDACIs. Moreover, TPB may antagonize the potential side effects of GM by inhibiting high dose GM-induced inflammatory cytokine production. Thus, combination of GM and TPB provides a unique and effective option in reducing the latent HIV-1 reservoir.

OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection
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Background {#jve1_3-5-sec-0001}
==========

Individuals who initiate antiretroviral therapy (ART) during acute HIV infection (AHI) have a lower frequency of latently infected cells and could have a greater chance for viremic control after treatment interruption (TI).

Methods {#jve1_3-5-sec-0002}
=======

A randomized study of vorinostat/hydroxychloroquine/maraviroc (VHM, n= 10; 8 Fiebig III/ 2 Fiebig IV) plus ART vs. ART alone (n=5; all Fiebig III) given for 10 weeks, followed by TI at week 10 was conducted in individuals treated since AHI with viral load (VL) suppression for \>48 weeks and CD4 ≥ 450 cells/mm^3^. The VHM arm received 3 cycles of vorinostat 400 mg/day (14 days on/14 days off) plus hydroxychloroquine (400 mg/day) and maraviroc (1200 mg/day). VL was monitored weekly after TI. ART was resumed when confirmed VL\>1000 copies/ml.

Results {#jve1_3-5-sec-0003}
=======

The participants were mainly male who were treated during Fiebig III AHI with high CD4 and about 3 years of VL suppression. Two individuals in the VHM arm had serious adverse events, and one withdrew from the study for renal insufficiency and thrombocytopenia.

Fourteen participants underwent TI (9 VHM+ART, 5 ART) and all experienced VL rebound with no difference between arms (range: 2--11 weeks). One participant in the ART arm had viremic control for 11 weeks. None had acute retroviral syndrome. All achieved VL suppression following ART and there was no change in genotypic resistance profile. Table OA3-5 LB.1.Characteristics at randomization and after TI in VHM+ART vs. ART armsCharacteristics, median (range)VHM+ARTARTAge at randomization, years/ gender28 (22--51)/ 9 male :1 female26 (24--34)/ 4male :1 femaleART duration, weeks224(79--294)155(100--295)CD4 count, cells/mm^3^634(501--1,106)1079(537--1,612)Total HIV DNA (copies/10E6 PBMCs)837(0--2,323)594(19--1,878)**POST-TREATMENT INTERRUPTION**Time from treatment interruption to VL detection, weeks3(2--5)3.1(3--11)VL levels at first detection, copies/ml222(33--41,822)156(52--395)Time from first VL detection to ART resumption, weeks1(0.1--4.1)2(1--5.3)Time from ART resumption to VL suppression, weeks2.9(0.9--10.9)2(1.9--3.9)

**Figure OA3-5 LB.1.** Viral load kinetics following treatment interruption in VHM+ART vs. ART arms

Conclusions {#jve1_3-5-sec-0004}
===========

In this proof-of-concept study, all 14 individuals who initiated ART during Fiebig III/IV AHI experienced VL rebound following treatment interruption regardless of VHM treatment.

OA4-1 Heterodimeric IL-15 induces effector cell activation and trafficking to the Germinal Centers of SIV infected Macaques
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Background {#jve1_4-1-sec-0001}
==========

IL-15 stimulates the growth and activation of NK cells and cytotoxic lymphocytes. We have produced heterodimeric IL-15 (hetIL-15), the authentic form of IL-15 found in the circulation, and demonstrated that administration of hetIL-15 in macaques shows improved pharmacokinetics and pharmacodynamics compared to previous preparations of IL-15 without significant side effects. We have previously reported that therapeutic DNA vaccination together with pDNA encoding hetIL-15 in ART-treated macaques induces T cell responses able to control viremia after ART release.

Methods {#jve1_4-1-sec-0002}
=======

Heterodimeric IL-15 (hetIL-15) was purified and tested in macaques upon subcutaneous (SC) administration. Phenotype and functional changes in lymphocyte subsets were monitored by flow cytometry and multiplexed confocal imaging (MCI).

Results {#jve1_4-1-sec-0003}
=======

Treatment with hetIL-15 resulted in a significant increase of CD8+ effector T cells and NK cells with activated cytotoxic phenotype (Granzyme^+^). This expanded T lymphocyte population was distributed in the tissues and was also present in secondary lymphoid organs where an increased frequency of Ag-specific effector and total effector CD8 T cells could be observed by both flow cytometry and MCI. A subset of CD8 T cells present in lymph nodes expresses CXCR5, indicating ability to migrate into germinal centers where chronically infected CD4^+^Tfh cells reside. MCI confirmed the presence of effector CD8 in germinal centers and showed that these cells are cytotoxic (GrzmB^+^) and actively proliferating (Ki67^+^) in response to hetIL-15.

Conclusions {#jve1_4-1-sec-0004}
===========

We are exploring the potential of hetIL-15 as a viral reservoir reducing agent in ART-treated SIV infected macaques therapeutically vaccinated with DNA. Effective levels of hetIL-15 can be delivered without side effects. hetIL-15 treatment in combination with DNA vaccination enhances access to virus sanctuary areas (germinal centers) and is a promising HIV eradication strategy.

OA4-2 HIV persists in colon and blood CCR6+CD4+ T cells during ART
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Background {#jve1_4-2-sec-0001}
==========

Peripheral blood CD4+ T-cells expressing the Th17 marker CCR6 are highly permissive to HIV. Retinoic acid (RA), a gut-homing inducer, increases HIV integration/replication only in CCR6+ T-cells; this further supports the role of the gut in HIV disease progression. Herein, we investigated the contribution of CCR6+ T-cells from the colon and blood to viral persistence during antiretroviral therapy (ART) and tested the ability of RA to reactivate latent HIV in these cells.

Methods {#jve1_4-2-sec-0002}
=======

Experiments were performed on matched blood/colon biopsy samples (n=7) and PBMC collected by leukapheresis (n=14) from chronically HIV-infected subjects aviremics under ART. Cells were extracted from colon biopsies by enzymatic digestion; then, memory CCR6+/CCR6- CD4+ T-cell subsets were sorted by flow cytometry (BD AriaIII). Blood total (T~M~, CD45RA-), effector (T~EM~, CD45RA-CCR7-) and central memory (T~CM~, CD45RA-CCR7+) CD4+ T-cells expressing or not CCR6 and producing cytokines (IL-17A or IFN-g) were also sorted by flow cytometry. Integrated HIV genomes were quantified by real-time PCR. HIV reactivation was induced by stimulation with CD3/CD28 Abs in the presence or absence of RA (10 nM) and/or ART for 9 days. Levels of HIV-RNA in cell-culture supernatants were quantified by real-time RT-PCR.

Results {#jve1_4-2-sec-0003}
=======

Memory CCR6+ compared to CCR6- T-cells isolated from the blood and colon biopsies were highly enriched in integrated HIV-DNA (median blood: 2,298 *vs*. 830, p=0.0041; median colon: 2,484 *vs*. 1,463 HIV-DNA copies/10^6^ cells; p=0.01). Among the T~M~ pool in the blood, CCR6+ T~CM~ showed the highest levels of integrated HIV-DNA. Upon TCR triggering, HIV reactivation was preferentially observed in blood CCR6+ compared to CCR6- T~M~, T~CM~, and T~EM~; exposure to RA further induced HIV reactivation in CCR6+ T-cells, including cells producing IL-17A.

Conclusions {#jve1_4-2-sec-0004}
===========

We identified CCR6 as a marker for CD4+ T-cells enriched in HIV reservoirs in the blood and the colon of ART-treated subjects and demonstrated that HIV-DNA persists in IL-17-producing cells. The finding that RA promotes HIV latency reversal in a TCR-dependent manner indicates an important contribution of the intestinal environment to viral persistence and reactivation. Understanding molecular mechanisms of HIV persistence in Th17 cells will be critical for the design of therapeutic strategies aimed at viral eradication.

OA4-3 PD-1 blockade combined with ART improves SIV-specific CD8 T cell function and enhances control of pathogenic SIV after ART interruption
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Background {#jve1_4-3-sec-0001}
==========

Previous studies have shown high levels of programmed death-1 (PD-1) expression on HIV/SIV specific CD8 T cells regulate their exhaustion during chronic infection. Studies have also shown PD-1+ CD4 T cells constitute a significant fraction of viral reservoirs under highly suppressive anti-retroviral therapy (ART). Here we tested the influence of PD-1 blockade administered during the initiation of ART and under fully suppressive ART on both dysfunctional CD8 T cells and latently infected CD4 T cells using a primatized anti-human PD-1 Ab.

Methods {#jve1_4-3-sec-0002}
=======

PD-1 blockade was performed in two phases after SIVmac251 infection in rhesus macaques (RMs). In Phase I, 5 infusions were administered over 14 days at 3 mg/kg dose at 10 days prior to the initiation of ART. In Phase II, 3 monthly infusions were administered at 10 mg/kg starting from 32 weeks post ART. ART was interrupted at 2 weeks after the final PD-1 Ab infusion.

Results {#jve1_4-3-sec-0003}
=======

Administration of PD-1 blockade during Phase I resulted in rapid proliferation of total CD8 and CD4 T cells, proliferation of SIV-specific CD8 T cells with higher cytotoxic potential and polyfunctionality (p\<0.05). Impressively, the PD-1 Ab treated animals showed more rapid viral suppression (42 days in the PD-1 group versus 140 days in saline group; p=0.01) and greater reconstitution of Th17 cells in the rectal mucosa (p=0.01) following initiation of ART. During phase II, there was a proliferation of total CD8 and CD4 T cells but this was much lower compared to Phase I. Interestingly, PD-1 blockade during Phase II resulted in transient but significant increases in viremia. Following ART interruption, PD-1 Ab treated animals showed up to 80-fold reduction in set point viremia compared to set point levels prior to initiation of ART. Analyses on live whole body imaging for virus-infected cells and viral out growth assays to determine the viral reservoirs are in progress.

Conclusions {#jve1_4-3-sec-0004}
===========

These results demonstrate that PD-1 blockade can be combined effectively with ART both to restore SIV-specific CD8 T cell function and possibly destabilizing the viral reservoir under ART, and have implications for developing potent approaches for achieving functional cure for HIV.

OA4-4 Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing
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Background {#jve1_4-4-sec-0001}
==========

The success of "shock and kill" HIV-1 cure strategies depend on two factors: 1) the induction of viral transcriptional activation from HIV-1 latently infected cells by latency reversing agents (LRAs); and 2) the killing of reactivated cells by cytotoxic T-lymphocytes (CTLs). However, functional differences between CTLs may affect the recognition of HIV-1 reactivated cells.

Here, we investigate the contribution of LRAs to HIV-1 protein expression for CTL recognition and killing, and we evaluate the impact of TCR avidity and immune exhaustion in CTL efficacy.

Methods {#jve1_4-4-sec-0002}
=======

We develop an HIV-1 "Resting--Like cell model" (RELI) in U937-HLA-B\*2705 cells. With the use of RELI, we measure HIV-1 reactivation after treatment with a panel of HDACs alone or in combination with Bryostatin. Moreover, we assess CTL recognition and killing in cocultures of LRAs-treated resting cells with HLA-matched CTLs. We measure CD107a/MIP1β secretion as a surrogate marker of HIV-1 recognition in CTLs. We quantify killing of reactivated cells by differences in p24 and total HIV-1 Gag DNA in absence or presence of CTLs. Moreover, we evaluate the impact of TCR-avidity and immune exhaustion in response to HIV-1 expression.

Results {#jve1_4-4-sec-0003}
=======

We observe a significant increase in HIV-1 p24 and CD107a/MIP1β secretion after LRAs treatment, reaching the maximum CTL activation with SAHA-treated conditions (p\<0.05). There is a correlation between CD107a/MIP1β expression in CTLs and HIV-1 reactivation (Spearman p\<0.0001). Moreover, CTL activation leads to the elimination of p24 positive LRAs-treated cells (85--95%). Effective killing translates into a reduction in total HIV Gag DNA levels but not to complete clearance of latently infected cells. Though HIV-1 reactivation and CTL cytokine secretion vary across LRAs and CTL tested. Indeed, differences in TCR avidity influence CD107a/MIP1β secretion in response to LRA-reactivated cells. In addition, preliminary data demonstrate that up-regulation of LAG3, TIM3, and CD39 expression in CTL, due to continuous antigen stimulation, results in diminished CD107a/MIP1β secretion in response to HIV-1.

Conclusions {#jve1_4-4-sec-0004}
===========

LRAs induce HIV-1 proteins expression for effective CTL recognition and killing of latently infected cells. However, differences in LRAs potency and/or CTL functionality should be taken into account to design effective "shock and kill" cure therapeutic strategies.

OA4-5 LB SIV persistence in ART-treated infant rhesus macaques
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Background {#jve1_4-5-sec-0001}
==========

Of the estimated 37 million people worldwide infected by HIV, 2.6 million are children. While antiretroviral therapy (ART) greatly reduces the mortality and morbidity of HIV infection, this treatment is not a cure due to the persistence of the virus in reservoirs. A fundamental barrier to an HIV cure is our incomplete understanding of anatomic reservoirs that are difficult to study in humans. Given the specific characteristics of the infant immune system, pediatric studies of the HIV reservoir are of critical importance.

Methods {#jve1_4-5-sec-0002}
=======

Infant rhesus macaques (RM) were orally infected with SIV~mac251~ and treated with a potent 3-drug ART regimen (PMPA+FTC+DTG) initiated 35 days post-infection. Elective necropsy was performed after 6--9 months of ART and tissue levels of SIV, ART drugs, and immune activation in ART-suppressed infant RM were compared to those of viremic infants and ART-treated adult macaques.

Results {#jve1_4-5-sec-0003}
=======

For the first time, we demonstrate persistent suppression of viremia below the limit of detection of our standard viral load assay in SIV-infected infant RM treated with ART. In keeping with results from HIV-infected infants, plasma viral loads declined to \<60 copies/ml over a range of 4--22 weeks after ART initiation. State-of-the-art detection of SIV-RNA in tissues at necropsy using SIV RNAscope revealed reduced SIV-RNA in the spleen, lymph nodes, and lymphoid aggregates of the gut but similar levels in the brain and gut lamina propria of ART-treated infant RM compared to viremic infant RM. ART drug levels were readily detected in plasma, but were undetectable in the brain and heterogeneous in the lymph nodes and colon of infant RM as measured by infrared matrix-assisted laser desorption-electrospray ionization (IR-MALDESI). Compared to viremic infant RM, TNF-a and Mx-1 in lymph nodes, spleen, ileum and brain and soluble CD14 in plasma were decreased in ART-suppressed infants.

Conclusions {#jve1_4-5-sec-0004}
===========

Using our model of pediatric SIV infection and ART, we provide the first description of virus and drug levels in infant tissues. This experimental *in vivo* platform can be applied to further study SIV reservoirs and test cure strategies in the period of infancy.
